Avadel Pharmaceuticals' stock is undervalued due to peak sales potential, along with the possibility of a buyout. Click here ...

Although there is no cure for narcolepsy, medication and lifestyle changes can help manage the symptoms. Medicines that ...

An expert discusses how key symptoms of narcolepsy, such as excessive daytime sleepiness and cataplexy, impact daily functioning and quality of life, along with the primary differences between type 1 ...

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the stock, ...

Most of Jazz’s early growth was attributable to Xyrem (sodium oxybate), a paediatric treatment for cataplexy and excessive daytime sleepiness in narcoleptic young people. In 2018, 74% of the ...

Read on for her answers to frequently asked questions about managing sleep attacks. Cataplexy is the least common symptom of these, and many people with narcolepsy never experience it. Narcolepsy ...

Lumryz garnered full FDA approval to treat excessive daytime sleepiness or cataplexy in adults with narcolepsy in the spring of 2023. This product is a once-daily formulation of sodium oxybate.

Avadel’s commercial product, LUMRYZ TM, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients ...

From modest beginnings, Melbourne’s annual Midsumma Festival has grown into an iconic celebration of the LGBTQIA+ community – and remains as essential as ever.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President ...